Clinical Trial

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Protocol Amendment History 1 change
minor Completion pushed: 2027-09 -> 2028-09 2026-07-11
Trial Details
NCT Number NCT06976268
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Parkinson Disease
Enrollment 550 participants
Start Date 2025-05-28
Primary Completion 2027-08 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-07